Morningstar

Health Canada Approves Merck's Subcutaneous Version of Keytruda Cancer Drug

Provided by Dow Jones

By Adriano Marchese 




  Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. 



  Health Canada has approved Keytruda SC, which is a new subcutaneous formulation of Merck's anti-PD-1 therapy called pembrolizumab. 



  The decision to approve the new version is based on results from pivotal trial 3475A-D77, it said, where the subcutaneous formulation was shown to deliver similar drug levels and effectiveness as the IV version when used with chemotherapy in certain lung-cancer patients. 



  The approval allows Merck to market the under-the-skin version of Keytruda in Canada, though the company said its rollout will depend on provincial and territorial reimbursement decisions. 





  Write to Adriano Marchese at adriano.marchese@wsj.com 





  (END) Dow Jones Newswires



  February 17, 2026 11:38 ET (16:38 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
 
Plus, a deep dive on SpaceX’s bid to challenge US telecoms. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
Why This Vanguard ETF Is One of the Best
 
Vanguard Total International Stock is appealing for several reasons. 
 
 
Zachary Evens 
 
 
 
6 ETFs To Diversify Away From AI
 
A difficult problem has an easy solution. 
 
 
Daniel Sotiroff 
 
 
 
The Best AI Stocks to Buy Now
 
Artificial intelligence stocks continue to attract investors, thanks to industry momentum and appealing valuations. 
 
 
Tori Brovet 
 
 
 
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
 
Despite a looming patent cliff, a strong drug pipeline and 4.1% yield give investors reasons for optimism. 
 
 
Karen Andersen, CFA 
 
 
 
 

			Sponsor Center